The 'Silent Surge' of Drug-Resistant Fungi: A Growing Global Concern

Paul Verweij, a professor of clinical mycology at Radboud University Medical Center in the Netherlands, has expressed concern about the rise of drug-resistant fungi, describing it as a "silent surge." Verweij and 50 international scientists have published a call for action against drug-resistant fungi in the journal Nature Medicine.

Why Are Fungi So Difficult to Treat?

The similarity between human cells and fungal cells makes developing new antifungal drugs difficult. This biological challenge is reflected in the fact that only five classes of antifungals have been developed in the past 75 years.

A significant factor in the development of resistance is the use of agricultural fungicides, which are chemically similar to medical antifungal drugs like azoles. Fungi can develop resistance to these fungicides, which can also reduce the effectiveness of medical treatments.

Furthermore, fungal spores can travel long distances through the air, potentially spreading resistant strains from agricultural settings to other regions.

The Impact of Resistant Infections

Fungal infections range from severe, life-threatening infections in immunocompromised patients (e.g., bloodstream yeast or lung mold) to non-life-threatening skin, hair, and nail infections.

Resistance is increasing in both categories. A study in the Netherlands found a 20% higher mortality rate for infections resistant to azole antifungal drugs compared to treatable ones.

Lower-income countries face particular challenges due to limited resources for diagnostics, infection control, and patient follow-up in hospitals.

A Path Forward and Growing Awareness

Proposed measures include monitoring and potentially reducing unnecessary agricultural fungicide use, and assessing new fungicides for potential cross-resistance with human pathogens.

Verweij noted that awareness is growing, citing the World Health Organization's first fungal pathogen list in 2022 and the ongoing revision of its global action plan on antimicrobial resistance to better address fungi.

He stated that further basic work is needed, such as developing diagnostic tools, establishing surveillance systems, and setting up laboratory networks, but funding for these initiatives can be difficult to secure.